

Association of Dopamine Agonist Use With Impulse Control

Archives of Neurology

63, 969

DOI: [10.1001/archneur.63.7.969](https://doi.org/10.1001/archneur.63.7.969)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Parkinson Disease: An Update. <i>Neurologist</i> , 2004, 10, 185-194.	0.4	29
2	Dopamine receptor agonists linked with impulse control disorders. <i>Reactions Weekly</i> , 2006, &NA;, 4.	0.0	0
3	Recent Publications on Medications and Pharmacy. <i>Hospital Pharmacy</i> , 2006, 41, 899-904.	0.4	0
5	Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 517-519.	0.9	204
6	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 699-710.	1.4	6
7	Medication-Related Impulse Control and Repetitive Behaviors in Parkinson Disease. <i>Archives of Neurology</i> , 2007, 64, 1089.	4.9	381
8	Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1329-1335.	0.9	9
9	Medication-related impulse control and repetitive behaviors in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2007, 20, 484-492.	1.8	134
11	Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 516-519.	1.1	56
12	Relating mode of action to clinical practice: Dopaminergic agents in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 466-479.	1.1	49
13	Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1178-1181.	0.8	72
15	Community and Long-Term Care Management of Parkinson's Disease in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 663-680.	1.3	9
16	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 664-672.	2.7	84
17	Etiologic and Phenotypic Similarities between Medication-Induced Syndromes and Courts' Customary Interpretation of Mental Disease in Exculpatory Defenses. <i>Journal of Psychiatry and Law</i> , 2007, 35, 125-146.	0.2	0
19	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. <i>Movement Disorders</i> , 2007, 22, 590-591.	2.2	68
20	Internet gambling and other pathological gambling in Parkinson's disease: A case series. <i>Movement Disorders</i> , 2007, 22, 591-593.	2.2	27
21	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. <i>Movement Disorders</i> , 2007, 22, 1757-1763.	2.2	246
22	Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. <i>Movement Disorders</i> , 2007, 22, 2221-2228.	2.2	96

#	ARTICLE	IF	CITATIONS
23	Predictors of punning in Parkinson's disease: Results from a questionnaire survey. <i>Movement Disorders</i> , 2007, 22, 2339-2345.	2.2	53
24	Decision-making with explicit and stable rules in mild Alzheimer's disease. <i>Neuropsychologia</i> , 2007, 45, 1632-1641.	0.7	111
25	Management of impulse control disorders in Parkinson's disease. <i>Current Treatment Options in Neurology</i> , 2007, 9, 189-197.	0.7	30
26	Prevalence of Problem and Pathological Gambling in Parkinson's Disease. <i>Journal of Gambling Studies</i> , 2008, 24, 411-422.	1.1	42
27	Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness. <i>Psychopharmacology</i> , 2008, 196, 221-232.	1.5	217
28	Dopamine dysregulation syndrome. <i>Journal of Neurology</i> , 2008, 255, 14-18.	1.8	8
29	Parkinson's disease-related disorders in the impulsive-compulsive spectrum. <i>Journal of Neurology</i> , 2008, 255, 48-56.	1.8	64
30	Long-term follow-up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 75-80.	2.2	213
31	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.	2.2	131
32	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1573-1579.	2.2	106
33	Current Status of Symptomatic Medical Therapy in Parkinson's Disease. <i>Neurotherapeutics</i> , 2008, 5, 164-180.	2.1	40
34	DEVELOPMENT OF A NEW ASSAY FOR EVALUATION OF L-3,4-DIHYDROXYPHENYLALANINE CYTOTOXICITY IN CATALASE-MUTANT ESCHERICHIA COLI. <i>Environmental Toxicology and Chemistry</i> , 2008, 27, 1768.	2.2	0
35	Impulse Control and Related Disorders in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 85-107.	1.8	109
36	Advances in the genetics of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 21-34.	2.8	27
37	Reward pathways in Parkinson's disease: Clinical and theoretical implications. <i>Psychiatry and Clinical Neurosciences</i> , 2008, 62, 203-213.	1.0	28
38	The neurobiology and genetics of impulse control disorders: Relationships to drug addictions. <i>Biochemical Pharmacology</i> , 2008, 75, 63-75.	2.0	428
41	Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson's Disease. <i>CNS Drugs</i> , 2008, 22, 563-586.	2.7	79
42	Predictors of impulsivity and reward seeking behavior with dopamine agonists. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 28-32.	1.1	183

#	ARTICLE	IF	CITATIONS
43	Psychosocial issues in young-onset Parkinson's disease: Current research and challenges. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 143-150.	1.1	34
44	Sexual dysfunction in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 451-456.	1.1	81
45	Parkinson's disease: clinical features and diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 368-376.	0.9	3,887
48	Adverse Events from the Treatment of Parkinson's Disease. <i>Neurologic Clinics</i> , 2008, 26, 65-83.	0.8	27
49	Is Dopamine Agonist Therapy Associated with Developing Pathological Gambling in Parkinson's Disease Patients?. <i>European Neurology</i> , 2008, 59, 183-186.	0.6	8
50	Cognitive Impairment in Parkinson's Disease and Dementia with Lewy Bodies: A Spectrum of Disease. <i>NeuroSignals</i> , 2008, 16, 24-34.	0.5	46
51	Effects of Potential Agonist-Replacement Therapies for Stimulant Dependence on Inhibitory Control in Cocaine Abusers. <i>American Journal of Drug and Alcohol Abuse</i> , 2008, 34, 293-305.	1.1	16
52	The safety of dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 111-127.	1.0	9
53	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1604-11.	4.9	127
54	The neurobiology of pathological gambling and drug addiction: an overview and new findings. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2008, 363, 3181-3189.	1.8	419
55	The Treatment of Early Parkinson's Disease. , 2008, , 49-70.		1
56	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
57	Impulse-Control Disorders in Parkinson's Disease. <i>CNS Spectrums</i> , 2008, 13, 690-698.	0.7	60
58	Drugs that affect autonomic functions or the extrapyramidal system. <i>Side Effects of Drugs Annual</i> , 2008, , 170-179.	0.6	0
59	D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 1068-1088.	1.0	19
60	Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease. <i>Neurologist</i> , 2008, 14, 89-99.	0.4	60
61	Update on the use of pramipexole in the treatment of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 337.	1.0	47
62	Dopamine Agonist Increases Risk Taking but Blunts Reward-Related Brain Activity. <i>PLoS ONE</i> , 2008, 3, e2479.	1.1	134

#	ARTICLE	IF	CITATIONS
63	STEADY-STATE ASSESSMENT OF IMPULSIVE CHOICE IN LEWIS AND FISCHER 344 RATS: BETWEEN-CONDITION DELAY MANIPULATIONS. <i>Journal of the Experimental Analysis of Behavior</i> , 2008, 90, 333-344.	0.8	50
64	Prevalence of hypersexual behavior in Parkinson's disease patients: Not restricted to males and dopamine agonist use. <i>International Journal of General Medicine</i> , 2009, 2, 57.	0.8	22
66	Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction. <i>Current Drug Abuse Reviews</i> , 2009, 2, 11-25.	3.4	69
67	Neuropsychiatry of Parkinson's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2009, 67, 930-939.	0.3	35
68	Reward networks in the brain as captured by connectivity measures. <i>Frontiers in Neuroscience</i> , 2009, 3, 350-362.	1.4	96
69	Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. <i>Postgraduate Medical Journal</i> , 2009, 85, 590-596.	0.9	48
70	The scientific and clinical basis for the treatment of Parkinson disease (2009). <i>Neurology</i> , 2009, 72, S1-136.	1.5	685
71	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 193-205.	0.6	11
72	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 206-215.	0.6	12
73	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.5	52
74	Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. <i>Brain</i> , 2009, 132, 1376-1385.	3.7	475
75	Serotonergic and Dopaminergic Modulation of Gambling Behavior as Assessed Using a Novel Rat Gambling Task. <i>Neuropsychopharmacology</i> , 2009, 34, 2329-2343.	2.8	306
76	Decision making under risk and under ambiguity in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1901-1908.	0.7	65
77	Increased Frequency and Range of Sexual Behavior in a Patient with Parkinson's Disease After Use of Pramipexole: A Case Report. <i>Journal of Sexual Medicine</i> , 2009, 6, 1177-1180.	0.3	33
78	Dopaminergic and serotonergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide. <i>Brain Research</i> , 2009, 1265, 196-204.	1.1	72
79	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. <i>Lancet Neurology</i> , 2009, 8, 929-937.	4.9	169
80	Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. <i>Lancet Neurology</i> , 2009, 8, 1140-1149.	4.9	337
81	Dopamine and impulse control disorders in Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, S93-S100.	2.8	120

#	ARTICLE	IF	CITATIONS
82	Psychotic and compulsive symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 738-744.	2.2	33
83	Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 899-905.	2.2	94
84	Serotonin and Parkinson's disease: On movement, mood, and madness. <i>Movement Disorders</i> , 2009, 24, 1255-1266.	2.2	146
85	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	2.2	192
86	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1461-1467.	2.2	394
87	Association of <i>DRD3</i> and <i>GRIN2B</i> with impulse control and related behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1803-1810.	2.2	148
88	Validity of a self-rated method to identify a lifetime history of depression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2436-2438.	2.2	2
89	Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. <i>Movement Disorders</i> , 2009, 24, 2430-2431.	2.2	19
90	Do autonomic function tests in people with Parkinson's disease predict survival rates at 7 years follow-up?. <i>Movement Disorders</i> , 2009, 24, 2432-2434.	2.2	10
91	Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. <i>Movement Disorders</i> , 2009, 24, 2316-2327.	2.2	32
92	Remission of acute psychotic anxious depression in a patient with Parkinson's disease after treatment with quetiapine. <i>Movement Disorders</i> , 2009, 24, 2431-2432.	2.2	0
93	Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2434-2435.	2.2	8
94	Identification of a novel THAP1 mutation at R29 amino acid residue in sporadic patients with early onset dystonia. <i>Movement Disorders</i> , 2009, 24, 2428-2429.	2.2	32
95	Dopamine dysregulation syndrome in a patient with early onset Parkinsonism and Parkin gene mutations. <i>Movement Disorders</i> , 2009, 24, 2442-2443.	2.2	10
96	HIV-associated parkinsonism with levodopa-induced dyskinesia and response to highly active antiretroviral therapy. <i>Movement Disorders</i> , 2009, 24, 2441-2442.	2.2	12
97	Subacute dopa-responsive parkinsonism after successful surgical treatment of aqueductal stenosis. <i>Movement Disorders</i> , 2009, 24, 2438-2440.	2.2	8
98	Subthalamic deep brain stimulation and impulse control in Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 493-497.	1.7	179
99	Personality, Addiction, Dopamine: Insights from Parkinson's Disease. <i>Neuron</i> , 2009, 61, 502-510.	3.8	313

#	ARTICLE	IF	CITATIONS
100	Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2009, 16, 1148-1152.	0.8	220
101	Impulse control disorders in Parkinson's disease in a Chinese population. <i>Neuroscience Letters</i> , 2009, 465, 6-9.	1.0	75
102	Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. <i>Drug Safety</i> , 2009, 32, 475-488.	1.4	80
105	Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 310-316.	1.4	55
106	What do clinical trials tell us about treating patients?. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S34-S37.	1.1	11
107	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S110-S113.	1.1	75
108	Treatment of young-onset Parkinson's disease: role of dopamine receptor agonists. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S71-S75.	1.1	21
109	Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S111-S115.	1.1	101
110	Pathologic Gambling: Biological and Clinical Considerations. <i>Journal of Addiction Medicine</i> , 2009, 3, 111-119.	1.4	14
111	Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. <i>Behavioural Pharmacology</i> , 2009, 20, 363-379.	0.8	57
112	Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine. <i>Clinical Neuropharmacology</i> , 2009, 32, 59-62.	0.2	30
113	Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. <i>Behavioural Pharmacology</i> , 2009, 20, 492-504.	0.8	24
114	Cognitive and Personality Features in Parkinson Disease: 2 Sides of the Same Coin?. <i>Cognitive and Behavioral Neurology</i> , 2009, 22, 258-263.	0.5	27
115	Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 310-316.	1.4	167
116	Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 549.	1.0	12
117	Outcomes of Patients with Parkinson Disease and Pathological Gambling. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 473-477.	0.3	19
118	Impulse Control Disorder and Piribedil. <i>Clinical Neuropharmacology</i> , 2010, 33, 11-13.	0.2	16
119	ETHICAL PERSPECTIVES IN NEUROLOGY. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2010, 16, 166-169.	0.4	0

#	ARTICLE	IF	CITATIONS
120	Drugs that affect autonomic functions or the extrapyramidal system. <i>Side Effects of Drugs Annual</i> , 2010, 32, 281-294.	0.6	0
121	Effects of pramipexole on impulsive choice in male wistar rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 267-276.	1.3	33
123	Impulsive choice and response in dopamine agonist-related impulse control behaviors. <i>Psychopharmacology</i> , 2010, 207, 645-659.	1.5	184
124	Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders. <i>Journal of Neurology</i> , 2010, 257, 276-283.	1.8	38
125	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2010, 9, 1200-1213.	4.9	753
126	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	2.8	132
127	New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, S104-9.	2.2	39
128	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	2.2	130
129	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1660-1669.	2.2	138
130	Dopamine release in ventral striatum of pathological gamblers losing money. <i>Acta Psychiatrica Scandinavica</i> , 2010, 122, 326-333.	2.2	105
131	Insights into pathophysiology of punting reveal possible treatment strategies. <i>Molecular Psychiatry</i> , 2010, 15, 560-573.	4.1	83
132	School problems and suicide in Japanese young people. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 214-215.	1.0	2
133	Skin picking in Parkinson's disease: A behavioral side-effect of dopaminergic treatment?. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 214-214.	1.0	11
134	PRECLINICAL STUDY: FULL ARTICLE: The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended access. <i>Addiction Biology</i> , 2010, 15, 312-323.	1.4	46
135	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.9	1,244
136	Dopamine Agonist Withdrawal Syndrome in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 58-63.	4.9	299
137	Dopamine, Reward, and Frontostriatal Circuitry in Impulse Control Disorders in Parkinson's Disease: Insights from Functional Imaging. <i>Clinical EEG and Neuroscience</i> , 2010, 41, 87-93.	0.9	29
138	Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study. <i>International Journal of Impotence Research</i> , 2010, 22, 325-335.	1.0	24

#	ARTICLE	IF	CITATIONS
139	Therapy of the Motor Features of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 252-272.	0.1	1
140	Psychiatric Issues in Parkinson's Disease. Blue Books of Neurology, 2010, 34, 213-228.	0.1	3
141	Compulsive Behaviors in Patients With Parkinson's Disease. Neurologist, 2010, 16, 192-195.	0.4	20
143	Detection of Impulse Control Disorders in Parkinson Disease Patients. Neurologist, 2010, 16, 406-407.	0.4	14
144	Cognitive-behavioral therapy for psychogenic nonepileptic seizures. Neurology, 2010, 74, 1986-1994.	1.5	384
145	Pathological Gambling and Substance Use Disorders. American Journal of Drug and Alcohol Abuse, 2010, 36, 242-247.	1.1	118
146	Subthalamic nucleus stimulation influences expression and suppression of impulsive behaviour in Parkinson's disease. Brain, 2010, 133, 3611-3624.	3.7	148
147	Nonmotor symptoms in Parkinson's disease: the dark side of the moon. Future Neurology, 2010, 5, 851-871.	0.9	10
148	Frontal-striatal abnormalities underlying behaviours in the compulsive-impulsive spectrum. Journal of the Neurological Sciences, 2010, 289, 55-59.	0.3	88
149	Compulsive habits in restless legs syndrome patients under dopaminergic treatment. Journal of the Neurological Sciences, 2010, 290, 52-56.	0.3	56
150	Introduction to Behavioral Addictions. American Journal of Drug and Alcohol Abuse, 2010, 36, 233-241.	1.1	860
151	Long-Term Efficacy of Rasagiline in Early Parkinson's Disease. International Journal of Neuroscience, 2010, 120, 404-408.	0.8	29
152	Decision-making during gambling: an integration of cognitive and psychobiological approaches. Philosophical Transactions of the Royal Society B: Biological Sciences, 2010, 365, 319-330.	1.8	215
153	Impulsive smoking in a patient with Parkinson's disease treated with dopamine agonists. Journal of Clinical Neuroscience, 2010, 17, 539-540.	0.8	29
154	Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism and Related Disorders, 2010, 16, 202-207.	1.1	161
155	Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism and Related Disorders, 2010, 16, 334-337.	1.1	40
156	Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors. Neuron, 2010, 65, 135-142.	3.8	259
157	Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism. Neuroscience, 2010, 168, 477-486.	1.1	28

#	ARTICLE	IF	CITATIONS
158	A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. <i>Sleep Medicine</i> , 2010, 11, 512-519.	0.8	91
159	Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint?. <i>Annals of the New York Academy of Sciences</i> , 2010, 1187, 294-315.	1.8	161
160	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. <i>Progress in Brain Research</i> , 2010, 184, 177-192.	0.9	21
161	Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. <i>Brain</i> , 2011, 134, 36-49.	3.7	187
163	Iowa Gambling Task in Parkinson's Disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 395-409.	0.8	39
164	Impulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study. <i>Journal of the Neurological Sciences</i> , 2011, 310, 197-201.	0.3	31
165	Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 183-188.	0.3	42
166	Brain volume changes in Parkinson's disease and their relationship with cognitive and behavioural abnormalities. <i>Journal of the Neurological Sciences</i> , 2011, 310, 64-69.	0.3	70
167	Disordered Gambling: Etiology, Trajectory, and Clinical Considerations. <i>Annual Review of Clinical Psychology</i> , 2011, 7, 483-510.	6.3	97
168	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
170	The Roles of Dopamine and Serotonin in Decision Making: Evidence from Pharmacological Experiments in Humans. <i>Neuropsychopharmacology</i> , 2011, 36, 114-132.	2.8	192
171	Impulse control disorders and dopaminergic treatments in Parkinson's disease. <i>Revue Neurologique</i> , 2011, 167, 827-832.	0.6	6
172	Dianas quirÁrgicas en el tratamiento de enfermedades psiquiÁtricas. Desde el movimiento a las emociones. <i>Neurocirugía</i> , 2011, 22, 5-22.	0.2	6
173	Impulse control disorders in Parkinson's disease: clinical characteristics and implications. <i>Neuropsychiatry</i> , 2011, 1, 133-147.	0.4	31
174	Cognitive enhancement by drugs in health and disease. <i>Trends in Cognitive Sciences</i> , 2011, 15, 28-36.	4.0	223
175	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 153-155.	1.1	61
176	Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 295-296.	1.1	10
177	Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: A review. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 413-417.	1.1	118

#	ARTICLE	IF	CITATIONS
178	Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 379-381.	1.1	36
179	Impulse control disorders in Chinese Parkinson's disease patients: The effect of ergot derived dopamine agonist. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 635-637.	1.1	30
180	Impulsive Behavior and Associated Clinical Variables in Parkinson's Disease. <i>Psychosomatics</i> , 2011, 52, 41-47.	2.5	6
182	Advances in Drug Therapy: Alternative Treatments for the Control of Motor Fluctuations and Dyskinesias. , 0, , .		0
183	Dopamine-Induced Nonmotor Symptoms of Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-6.	0.6	33
184	Impulse Control Disorders Following Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease: Clinical Aspects. <i>Parkinson's Disease</i> , 2011, 2011, 1-9.	0.6	38
185	Available and emerging treatments for Parkinson's disease: a review. <i>Drug Design, Development and Therapy</i> , 2011, 5, 241.	2.0	34
186	Modulation of Habit Formation by Levodopa in Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e27695.	1.1	4
187	Pharmacological evaluation of the adequacy of marble burying as an animal model of compulsion and/or anxiety. <i>Behavioural Pharmacology</i> , 2011, 22, 711-713.	0.8	40
189	Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. <i>Addiction</i> , 2011, 106, 283-293.	1.7	79
190	Altruistic punishment in patients with Parkinson's disease with and without impulsive behaviour. <i>Neuropsychologia</i> , 2011, 49, 103-107.	0.7	18
191	Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson's Disease. <i>Experimental Neurology</i> , 2011, 231, 181-189.	2.0	25
192	Pathological gambling in Parkinson's disease: disease related or drug related?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 809-814.	1.4	7
193	An Eight Component Decision-Making Model for Problem Gambling:A Systems Approach to Stimulate Integrative Research. <i>Journal of Gambling Studies</i> , 2011, 27, 523-563.	1.1	20
194	Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson's disease. <i>Experimental Brain Research</i> , 2011, 213, 435-445.	0.7	68
195	Drug-Induced Impulse Control Disorders: A Prospectus for Neuroethical Analysis. <i>Neuroethics</i> , 2011, 4, 91-102.	1.7	19
196	Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. <i>BMC Neurology</i> , 2011, 11, 117.	0.8	107
197	Twice-daily, low-dose pramipexole in early Parkinson's disease: A randomized, placebo-controlled trial. <i>Movement Disorders</i> , 2011, 26, 37-44.	2.2	44

#	ARTICLE	IF	CITATIONS
198	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	2.2	139
199	Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 830-836.	2.2	104
200	Parkinson's disease: The quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011, 26, 1022-1031.	2.2	349
201	Reward processing abnormalities in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1451-1457.	2.2	38
202	Intertemporal choice in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2004-2010.	2.2	66
203	The <i>Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S2-41.	2.2	479
204	Pramipexole modulates the neural network of reward anticipation. <i>Human Brain Mapping</i> , 2011, 32, 800-811.	1.9	86
205	A_{2A} Adenosine Receptor Binding Parameters in Platelets from Patients Affected by Pathological Gambling. <i>Neuropsychobiology</i> , 2011, 63, 154-159.	0.9	1
206	Nonmotor problems in Parkinson disease. , 2011, , 183-196.		0
207	Possible Sites of Therapeutic Action in Restless Legs Syndrome: Focus on Dopamine and Î±&sub>2</sub> Ligands. <i>European Neurology</i> , 2011, 66, 18-29.	0.6	29
208	The risky business of dopamine agonists in Parkinson disease and impulse control disorders.. <i>Behavioral Neuroscience</i> , 2011, 125, 492-500.	0.6	92
209	Management of sexual dysfunction in Parkinson's disease. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 375-383.	1.5	91
210	Pharmacologic Safety Concerns in Parkinson's Disease: Facts and Insights. <i>International Journal of Neuroscience</i> , 2011, 121, 45-52.	0.8	18
211	Dose-Dependent Impulse Control Disorders in Piribedil Overdose. <i>Clinical Neuropharmacology</i> , 2012, 35, 49-50.	0.2	13
212	Comparison of Personality Characteristics in Parkinson Disease Patients With and Without Impulse Control Disorders and in Healthy Volunteers. <i>Cognitive and Behavioral Neurology</i> , 2012, 25, 25-33.	0.5	16
213	Impulsive and Compulsive Behaviors During Dopamine Replacement Treatment in Parkinson's Disease and Other Disorders. <i>Current Drug Safety</i> , 2012, 7, 63-75.	0.3	43
214	Impulse control disorders in Parkinson's disease: background and update on prevention and management. <i>Neurodegenerative Disease Management</i> , 2012, 2, 389-400.	1.2	10
215	VUV Photoionization and Dissociation of Tyramine and Dopamine: the Joint Experimental and Theoretical Studies. <i>Chinese Journal of Chemical Physics</i> , 2012, 25, 11-18.	0.6	5

#	ARTICLE	IF	CITATIONS
216	Exploring Hypersexual Behavior in Men with Parkinson's Disease: Is it Compulsive Sexual Behavior?. <i>Journal of Parkinson's Disease</i> , 2012, 2, 225-234.	1.5	13
217	Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?. <i>Therapeutic Advances in Neurological Disorders</i> , 2012, 5, 23-41.	1.5	22
218	The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. <i>Psychological Medicine</i> , 2012, 42, 1203-1215.	2.7	170
219	Deep Brain Stimulation and Behavioural Changes: Is Comedication the Most Important Factor?. <i>Neurodegenerative Diseases</i> , 2012, 9, 18-24.	0.8	10
220	Pathological Gambling: A Systematic Review of Biochemical, Neuroimaging, and Neuropsychological Findings. <i>Harvard Review of Psychiatry</i> , 2012, 20, 130-148.	0.9	84
221	A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease: first psychometric approach. <i>Journal of Neurology</i> , 2012, 259, 2299-2308.	1.8	28
222	Long-term use of pramipexole in the management of restless legs syndrome. <i>Sleep Medicine</i> , 2012, 13, 1280-1285.	0.8	103
223	Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 10-16.	1.1	39
224	Prescribing in Parkinson's disease: a story of hope and adverse events. <i>Practical Neurology</i> , 2012, 12, 335-340.	0.5	14
225	An update on the management of juvenile and young-onset Parkinson's disease. <i>Future Neurology</i> , 2012, 7, 581-593.	0.9	1
226	Is premature ejaculation an impulse control disorder?. <i>Medical Hypotheses</i> , 2012, 79, 59-62.	0.8	5
227	A case of multiple system atrophy with normal dopamine transporter imaging. <i>Journal of Neurology</i> , 2012, 259, 2729-2731.	1.8	6
228	Neuroplasticity and impulse control disorders. <i>Journal of the Neurological Sciences</i> , 2012, 316, 15-20.	0.3	5
230	Addictive behaviors and Parkinson's disease. <i>Revue Neurologique</i> , 2012, 168, 624-633.	0.6	26
231	A Combination of Dopamine Genes Predicts Success by Professional Wall Street Traders. <i>PLoS ONE</i> , 2012, 7, e30844.	1.1	24
232	Nonmotor Symptoms in Parkinson's Disease in 2012: Relevant Clinical Aspects. <i>Parkinson's Disease</i> , 2012, 2012, 1-15.	0.6	79
233	Epidemiology of Psychiatric Symptoms in Parkinson's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 1-12.	0.2	5
234	The Neuropsychopharmacology of Pathological Gambling. <i>Current Psychiatry Reviews</i> , 2012, 8, 20-24.	0.9	3

#	ARTICLE	IF	CITATIONS
236	Dopamine Agonists and the Suppression of Impulsive Motor Actions in Parkinson Disease. <i>Journal of Cognitive Neuroscience</i> , 2012, 24, 1709-1724.	1.1	66
237	Dysexecutive Syndrome. <i>Cognitive and Behavioral Neurology</i> , 2012, 25, 57-62.	0.5	14
238	Addiction and Parkinson's Disease. , 2012, , 363-374.		0
239	ADDICTION AS ABERRANT LEARNING—EVIDENCE FROM PARKINSON'S DISEASE. <i>Addiction</i> , 2012, 107, 248-250.	1.7	3
240	Compulsive buying in bipolar disorder: Is it a comorbidity or a complication?. <i>Journal of Affective Disorders</i> , 2012, 136, 797-802.	2.0	22
241	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. <i>Lancet Neurology</i> , The, 2012, 11, 429-442.	4.9	343
242	Dose dependent dopaminergic modulation of reward-based learning in Parkinson's disease. <i>Neuropsychologia</i> , 2012, 50, 583-591.	0.7	15
243	Are there ethnic differences in impulsive/compulsive behaviors in Parkinson's disease?. <i>European Journal of Neurology</i> , 2012, 19, 494-500.	1.7	29
244	Perceptions of cause and control of impulse control behaviours in people with Parkinson's disease. <i>British Journal of Health Psychology</i> , 2012, 17, 522-535.	1.9	11
245	Questionnaire for impulsive-compulsive disorders in Parkinson's Disease—Rating Scale. <i>Movement Disorders</i> , 2012, 27, 242-247.	2.2	263
247	Simultaneous blockade of dopamine and noradrenaline reuptake promotes disadvantageous decision making in a rat gambling task. <i>Psychopharmacology</i> , 2013, 225, 719-731.	1.5	90
248	Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 429-437.	1.8	27
249	Dopamine Agonist-Induced Impulse Control Disorders in a Patient with Prolactinoma. <i>Psychosomatics</i> , 2013, 54, 387-391.	2.5	16
250	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. <i>Brain</i> , 2013, 136, 400-411.	3.7	172
251	Reward Signals, Attempted Suicide, and Impulsivity in Late-Life Depression. <i>JAMA Psychiatry</i> , 2013, 70, 1020.	6.0	200
252	Rasagiline adjunct therapy in patients with Parkinson's disease: Post-hoc analyses of the PRESTO and LARGO trials. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 930-936.	1.1	29
253	Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. <i>Reviews in the Neurosciences</i> , 2013, 24, 267-78.	1.4	152
254	Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 964-969.	0.8	40

#	ARTICLE	IF	CITATIONS
255	A Systematic Review of Impulse Control Disorders in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 105-138.	1.5	118
256	Subthalamic stimulation modulates self-estimation of patients with Parkinson's disease and induces risk-seeking behaviour. <i>Brain</i> , 2013, 136, 3271-3281.	3.7	30
257	Diagnosis and treatment of impulse control disorders in patients with movement disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2013, 6, 175-188.	1.5	29
258	Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 698-700.	1.1	44
259	Inhibitory Effects of Pergolide and Cabergoline Formulations on Daily Plasma Prolactin Concentrations in Geldings and on the Daily Prolactin Responses to a Small Dose of Sulpiride in Mares. <i>Journal of Equine Veterinary Science</i> , 2013, 33, 773-778.	0.4	9
260	Prospective cohort study of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 327-333.	2.2	136
261	Pathological gambling in Parkinson's disease. A comprehensive review. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 645-653.	1.1	67
262	Handbook of Parkinson's Disease. , 2013, , .		14
263	Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive/Compulsive Disorders in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2013, 331, 76-80.	0.3	32
264	Initial Treatment of Parkinson's Disease: An Update. <i>Current Treatment Options in Neurology</i> , 2013, 15, 377-384.	0.7	5
265	Pramipexole-Induced Obsessive-Compulsive Symptoms in a Patient with Parkinson's Disease and Disgust Sensitivity. <i>Psychosomatics</i> , 2013, 54, 286-289.	2.5	3
266	Sleep and impulsivity in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 991-994.	1.1	37
267	Managing impulse control behaviours in Parkinson's disease: practical guidelines. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 160-166.	0.2	14
268	The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 141-149.	0.9	29
270	Impulse Control Disorder in a Patient on Long-Term Treatment With Bromocriptine for a Macroprolactinoma. <i>Clinical Neuropharmacology</i> , 2013, 36, 170-172.	0.2	15
271	Impulsivity and apathy in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2013, 7, 255-283.	0.6	81
272	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2013, 3, 139-144.	1.5	39
274	Impulse control disorders and related behaviors. , 2013, , 140-152.		3

#	ARTICLE	IF	CITATIONS
275	The Iowa Gambling Task and the three fallacies of dopamine in gambling disorder. <i>Frontiers in Psychology</i> , 2013, 4, 709.	1.1	17
276	Dopaminergic and Clinical Correlates of Pathological Gambling in Parkinson's Disease: A Case Report. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 95.	1.0	10
277	How central is dopamine to pathological gambling or gambling disorder?. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 206.	1.0	91
278	Neural and behavioral substrates of subtypes of Parkinson's disease. <i>Frontiers in Systems Neuroscience</i> , 2013, 7, 117.	1.2	24
279	Impulse Control Disorders in Parkinson's Disease: Crossroads between Neurology, Psychiatry and Neuroscience. <i>Behavioural Neurology</i> , 2013, 27, 547-557.	1.1	12
280	An update on the management of young-onset Parkinson's disease. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2013, 2, 53.	0.7	2
281	Multiple Modes of Impulsivity in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e85747.	1.1	116
282	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1093.	1.0	20
283	Impulsive and Compulsive Behaviors in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 318.	1.7	31
284	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 86.	1.0	19
285	The role of dopamine in risk taking: a specific look at Parkinson's disease and gambling. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 196.	1.0	43
286	Maladaptive Reward-Learning and Impulse Control Disorders in Patients with Parkinson's Disease: A Clinical Overview and Pathophysiology Update. <i>Journal of Movement Disorders</i> , 2014, 7, 67-76.	0.7	10
287	Gambling Disorder during Dopamine Replacement Treatment in Parkinson's Disease: A Comprehensive Review. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	19
288	Dopaminergic Influences on Emotional Decision Making in Euthymic Bipolar Patients. <i>Neuropsychopharmacology</i> , 2014, 39, 274-282.	2.8	33
289	Impulse control disorders and related behaviours (ICD-RBs) in Parkinson's disease patients: Assessment using "Questionnaire for impulsive-compulsive disorders in Parkinson's disease" (QUIP). <i>Annals of Indian Academy of Neurology</i> , 2014, 18, 49-59.	0.2	33
290	Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1028-1034.	2.2	44
291	Motor impulsivity in Parkinson disease: Associations with <i>COMT</i> and <i>DRD2</i> polymorphisms. <i>Scandinavian Journal of Psychology</i> , 2014, 55, 278-286.	0.8	17
292	Treating Compulsive Buying Disorder. <i>Current Treatment Options in Psychiatry</i> , 2014, 1, 315-324.	0.7	5

#	ARTICLE	IF	CITATIONS
293	Understanding Parkinson disease. <i>Nurse Practitioner</i> , 2014, 39, 1-10.	0.2	3
294	Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 840-844.	0.9	200
295	The Contribution of Apathy and Increased Learning Trials to Risky Decision-Making in Parkinson's Disease. <i>Archives of Clinical Neuropsychology</i> , 2014, 29, 100-109.	0.3	22
296	Pharmacological Treatment of Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1670.	3.8	1,097
297	Eating Disorders, Addictions and Substance Use Disorders. , 2014, , .		9
298	Rasagiline induced hypersexuality in Parkinson's disease. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 507-508.	0.8	21
299	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. <i>Pituitary</i> , 2014, 17, 150-156.	1.6	53
300	Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study. <i>Psychiatry Research</i> , 2014, 215, 448-452.	1.7	81
301	Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. <i>Clinical Endocrinology</i> , 2014, 80, 863-868.	1.2	103
302	Impulse Control Disorders in Parkinson's Disease Are Associated with Dysfunction in Stimulus Valuation But Not Action Valuation. <i>Journal of Neuroscience</i> , 2014, 34, 7814-7824.	1.7	73
303	Impulse control and repetitive behaviors in Parkinson's disease - Are there differences in the relation to dopamine agonist treatment?. <i>Journal of the Neurological Sciences</i> , 2014, 345, 252-253.	0.3	1
304	Study protocol: the JEU cohort study - transversal multi-axial evaluation and 5-year follow-up of a cohort of French gamblers. <i>BMC Psychiatry</i> , 2014, 14, 226.	1.1	16
306	Targeting impulsivity in Parkinson's disease using atomoxetine. <i>Brain</i> , 2014, 137, 1986-1997.	3.7	116
307	Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 23-30.	0.9	42
308	Enhanced creative thinking under dopaminergic therapy in Parkinson disease. <i>Annals of Neurology</i> , 2014, 75, 935-942.	2.8	57
309	Brain circuitry of compulsivity and impulsivity. <i>CNS Spectrums</i> , 2014, 19, 21-27.	0.7	52
310	Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration's Adverse Event database. <i>Journal of Behavioral Addictions</i> , 2014, 3, 21-26.	1.9	9
311	Intertemporal choice in Parkinson's disease and restless legs syndrome. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1330-1335.	1.1	26

#	ARTICLE	IF	CITATIONS
312	Translational Models of Gambling-Related Decision-Making. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 28, 93-120.	0.8	32
313	Compulsive Masturbation With Pramipexole for Antidepressant Augmentation in Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 485.	0.7	2
314	Doping for Chess Performance. , 2015, 05, .		1
315	Nonmotor symptoms in Parkinson's disease: classification and management. <i>Journal of Parkinsonism and Restless Legs Syndrome</i> , 2015, , 1.	0.8	5
316	Social behavioral changes in MPTP-treated monkey model of Parkinson's disease. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 42.	1.0	17
317	Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brain. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 49.	1.0	151
318	Multifaceted effects of noisy galvanic vestibular stimulation on manual tracking behavior in Parkinson's disease. <i>Frontiers in Systems Neuroscience</i> , 2015, 9, 5.	1.2	29
319	Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome – patient considerations. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2015, 5, 63.	0.7	2
320	Piribedil and Pathological Gambling in six Parkinsonian patients. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 115-118.	0.3	11
321	Sexuality in patients with Parkinson's disease, Alzheimer's disease, and other dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 130, 297-323.	1.0	38
322	Fiber grating compression of giant-chirped nanosecond pulses from an ultra-long nanotube mode-locked fiber laser. <i>Optics Letters</i> , 2015, 40, 387.	1.7	28
323	A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson's disease. <i>Psychiatry Research</i> , 2015, 225, 402-406.	1.7	12
324	Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. <i>Synapse</i> , 2015, 69, 183-189.	0.6	123
326	Does Response Inhibition Have Pre- and Postdiagnostic Utility in Parkinson's Disease?. <i>Journal of Motor Behavior</i> , 2015, 47, 29-45.	0.5	12
327	Pet Killing as a Manifestation of Impulse Control Disorder Secondary to Pramipexol. <i>Clinical Neuropharmacology</i> , 2015, 38, 55-56.	0.2	12
328	International validation of a behavioral scale in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2015, 30, 705-713.	2.2	88
329	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	2.2	63
330	Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 129, 19-25.	1.3	43

#	ARTICLE	IF	CITATIONS
331	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 121-127.	2.2	264
332	Improving Response Inhibition in Parkinson's Disease with Atomoxetine. <i>Biological Psychiatry</i> , 2015, 77, 740-748.	0.7	93
333	Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment. <i>Journal of Neurology</i> , 2015, 262, 7-20.	1.8	20
334	Dopaminergic Medication in Parkinson's Disease and Problem Gambling. <i>Journal of Gambling Studies</i> , 2015, 31, 1085-1106.	1.1	9
335	Reward-based decision making in pathological gambling: The roles of risk and delay. <i>Neuroscience Research</i> , 2015, 90, 3-14.	1.0	96
336	Impact of Sex on the Nonmotor Symptoms and the Health-Related Quality of Life in Parkinson's Disease. <i>Parkinson's Disease</i> , 2016, 2016, 1-12.	0.6	43
337	Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers. <i>Frontiers in Human Neuroscience</i> , 2016, 10, 523.	1.0	8
338	Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications. <i>Frontiers in Psychiatry</i> , 2016, 7, 110.	1.3	17
339	Introduction to Parkinson disease (PD) and its complications. <i>Mental Health Clinician</i> , 2016, 6, 229-235.	0.5	9
341	Human behavioral assessments in current research of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 68, 741-772.	2.9	58
342	Management of impulse control disorders in Parkinson's disease. <i>International Psychogeriatrics</i> , 2016, 28, 1597-1614.	0.6	16
343	Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. <i>Neurologia (English Edition)</i> , 2016, 31, 231-238.	0.2	15
344	Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease. <i>Journal of Cognitive Neuroscience</i> , 2016, 28, 710-723.	1.1	37
345	How close are we to individualized medicine for Parkinson's disease?. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 815-830.	1.4	21
346	Brainjacking: Implant Security Issues in Invasive Neuromodulation. <i>World Neurosurgery</i> , 2016, 92, 454-462.	0.7	95
347	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.	1.7	51
348	Impulse control disorders in Parkinson's disease: Predominant role of psychological determinants. <i>Psychology and Health</i> , 2016, 31, 1391-1414.	1.2	10
349	Neuropsychiatric manifestations of Parkinson's disease. <i>Australasian Psychiatry</i> , 2016, 24, 529-533.	0.4	8

#	ARTICLE	IF	CITATIONS
350	Long-term safety and effectiveness of pramipexole in tetrahydrobiopterin deficiency. <i>European Journal of Paediatric Neurology</i> , 2016, 20, 839-842.	0.7	14
351	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1889-1902.	0.9	37
352	Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2016, 6, 267-277.	1.5	28
353	A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2016, 30, 957-966.	2.0	1
354	The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. <i>Journal of the Neurological Sciences</i> , 2016, 368, 150-154.	0.3	115
355	Behavioral and Pharmacological Treatment of Compulsive Sexual Behavior/Problematic Hypersexuality. <i>Current Addiction Reports</i> , 2016, 3, 406-413.	1.6	4
357	COMT and ANKK1 Genetics Interact With Depression to Influence Behavior Following Severe TBI. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 920-930.	1.4	32
358	Dopamine D ₃ Receptors Modulate the Ability of Win-Paired Cues to Increase Risky Choice in a Rat Gambling Task. <i>Journal of Neuroscience</i> , 2016, 36, 785-794.	1.7	76
359	A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 181-198.	1.0	30
360	Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 63-70.	0.7	38
361	Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease. <i>Neuropsychopharmacology</i> , 2016, 41, 2171-2177.	2.8	43
362	Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 389-399.	1.4	22
363	The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 10-16.	1.1	48
364	A survey of impulse control disorders in Parkinson's disease patients in Shanghai area and literature review. <i>Translational Neurodegeneration</i> , 2016, 5, 4.	3.6	15
365	Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity. <i>Journal of the Neurological Sciences</i> , 2016, 362, 344-347.	0.3	22
367	Dopamine Selectively Modulates the Outcome of Learning Unnatural Action-Valence Associations. <i>Journal of Cognitive Neuroscience</i> , 2017, 29, 816-826.	1.1	8
368	Focused stimulation of dorsal subthalamic nucleus improves reactive inhibitory control of action impulses. <i>Neuropsychologia</i> , 2017, 99, 37-47.	0.7	37
369	Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. <i>Journal of Parkinson's Disease</i> , 2017, 7, 183-191.	1.5	48

#	ARTICLE	IF	CITATIONS
370	Possible Role of Serotonin and Selective Serotonin Reuptake Inhibitors in Suicidal Ideations and Attempts. <i>Journal of Pharmaceutical Sciences and Pharmacology</i> , 2017, 3, 54-70.	0.2	2
371	Parkinson Symptoms in Dementia with Lewy Bodies. , 2017, , 93-109.		1
372	Pramipexole Modulates Interregional Connectivity Within the Sensorimotor Network. <i>Brain Connectivity</i> , 2017, 7, 258-263.	0.8	9
374	Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 737-749.	1.4	7
375	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 783-789.	2.2	27
376	ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 317-324.	0.9	119
377	Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 172-179.	0.9	4
378	Longitudinal decline of driving safety in Parkinson disease. <i>Neurology</i> , 2017, 89, 1951-1958.	1.5	24
379	Subject-enabled analytics model on measurement statistics in health risk expert system for public health informatics. <i>International Journal of Medical Informatics</i> , 2017, 107, 18-29.	1.6	8
380	Response to Commentaries: Recognizing Hypersexuality as a Psychosexual Behavioral Problem and Advancing the Sexbehavior Cycle of Hypersexuality. <i>Archives of Sexual Behavior</i> , 2017, 46, 2279-2287.	1.2	6
382	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	2.5	29
383	Hypersexuality: A Critical Review and Introduction to the "Sexbehavior Cycle". <i>Archives of Sexual Behavior</i> , 2017, 46, 2231-2251.	1.2	124
384	Resting-state brain networks in patients with Parkinson's disease and impulse control disorders. <i>Cortex</i> , 2017, 94, 63-72.	1.1	53
385	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 679-717.	0.9	195
386	Chronic D _{2/3} agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns. <i>European Journal of Neuroscience</i> , 2017, 45, 159-166.	1.2	34
388	Pathological gambling in Parkinson's disease: what are the risk factors and what is the role of impulsivity?. <i>European Journal of Neuroscience</i> , 2017, 45, 67-72.	1.2	25
389	Neuropsychiatric symptoms in untreated Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 815-826.	1.0	37
390	Caregiver Burden and the Nonmotor Symptoms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 479-497.	0.9	57

#	ARTICLE	IF	CITATIONS
391	Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 145.	1.0	26
393	Impulse control disorders in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 1299-1312.	1.4	22
394	Independent and Complementary Validation of the QUIP-RS in Advanced Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 341-342.	0.8	3
395	Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease. <i>Neuropsychologia</i> , 2018, 109, 262-269.	0.7	14
396	Lack of Increase in Sexual Drive and Function After Dopaminergic Stimulation in Women. <i>Journal of Sex and Marital Therapy</i> , 2018, 44, 61-72.	1.0	6
397	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 6-13.	0.8	20
398	Motivational Sensitivities Linked to Impulsive Motor Errors in Parkinson's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 128-138.	1.2	6
399	Dopamine Agonists and Impulse Control Disorders: A Complex Association. <i>Drug Safety</i> , 2018, 41, 19-75.	1.4	101
400	Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels. <i>Psychopharmacology</i> , 2018, 235, 23-35.	1.5	12
401	Psychiatric Manifestation in Patients with Parkinson's Disease. <i>Journal of Korean Medical Science</i> , 2018, 33, e300.	1.1	58
402	Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. <i>Frontiers in Neurology</i> , 2018, 9, 1041.	1.1	11
403	An Integrative Biopsychosocial and Sex Positive Model of Understanding and Treatment of Impulsive/Compulsive Sexual Behavior. <i>Sexual Addiction and Compulsivity</i> , 2018, 25, 125-152.	0.9	29
404	Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 365-404.	0.9	0
406	Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease. <i>Brain and Behavior</i> , 2018, 8, e01008.	1.0	16
407	The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study. <i>Brain and Behavior</i> , 2018, 8, e01036.	1.0	21
408	Impulsivity in Parkinson's Disease Is Associated With Alterations in Affective and Sensorimotor Striatal Networks. <i>Frontiers in Neurology</i> , 2018, 9, 279.	1.1	26
409	Impulse-Control Disorders in Parkinson's Disease: A Meta-Analysis and Review of Case-Control Studies. <i>Frontiers in Neurology</i> , 2018, 9, 330.	1.1	39
410	Degenerative Movement Disorders of the Central Nervous System. , 2018, , 321-325.e3.		0

#	ARTICLE	IF	CITATIONS
411	Dysfunctional inhibitory control in Parkinsonâ€™s disease patients with levodopa-induced dyskinesias. <i>Journal of Neurology</i> , 2018, 265, 2088-2096.	1.8	23
412	Remote delivery of psychological interventions for Parkinson's disease. <i>International Psychogeriatrics</i> , 2018, 30, 1783-1795.	0.6	76
413	Sleep in Parkinsonâ€™s Disease with Impulse Control Disorder. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 68.	2.0	6
414	Longitudinal analysis of impulse control disorders in Parkinson disease. <i>Neurology</i> , 2018, 91, e189-e201.	1.5	175
415	Awareness and current knowledge of Parkinsonâ€™s disease: a neurodegenerative disorder. <i>International Journal of Neuroscience</i> , 2019, 129, 55-93.	0.8	57
416	Pathological Gambling in Parkinson's disease: Autonomic measures supporting impaired decisionâ€™making. <i>European Journal of Neuroscience</i> , 2019, 50, 2392-2400.	1.2	7
417	Depression as a Risk Factor for Impulse Control Disorders in Parkinson Disease. <i>Annals of Neurology</i> , 2019, 86, 762-769.	2.8	29
418	Gambling disorder. <i>Nature Reviews Disease Primers</i> , 2019, 5, 51.	18.1	233
419	Impulse control disorders in Parkinson disease and RBD. <i>Neurology</i> , 2019, 93, e675-e687.	1.5	44
420	Atomoxetine and citalopram alter brain network organization in Parkinsonâ€™s disease. <i>Brain Communications</i> , 2019, 1, fcz013.	1.5	10
421	Risk factors for impulse control disorders and related behaviors in Parkinsonâ€™s disease: secondary analyses of the ICARUS study. <i>Journal of Drug Assessment</i> , 2019, 8, 159-166.	1.1	8
422	Trait Impulsivity Is Independent of Mild Cognitive Impairment in a Parkinsonâ€™s Disease Cohort. <i>Parkinson's Disease</i> , 2019, 2019, 1-6.	0.6	4
423	Why would Parkinsonâ€™s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 100, 129-165.	2.9	17
424	Impulse control disorders in Parkinsonâ€™s disease: A systematic review on the psychometric properties of the existing measures. <i>PLoS ONE</i> , 2019, 14, e0217700.	1.1	4
426	Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. <i>Neuroscience Letters</i> , 2019, 707, 134313.	1.0	10
427	Parkinsonâ€™s disease management and impulse control disorders: current state and future perspectives. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 495-508.	1.4	7
428	Deep Brain Stimulation of the Subthalamic Nucleus Induces Impulsive Responses to Bursts of Sensory Evidence. <i>Frontiers in Neuroscience</i> , 2019, 13, 270.	1.4	2
429	Can Slot-Machine Reward Schedules Induce Gambling Addiction in Rats?. <i>Journal of Gambling Studies</i> , 2019, 35, 887-914.	1.1	5

#	ARTICLE	IF	CITATIONS
430	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 998-1018.	0.6	82
431	Creativity related to dopaminergic treatment: A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 169-173.	1.1	10
432	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019, 34, 447-452.	2.2	26
433	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Diseaseâ€“Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	1.1	9
434	Impulse Control Disorders in REM Sleep Behavior Disorder. <i>Current Treatment Options in Neurology</i> , 2019, 21, 23.	0.7	7
435	<p>A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1011-1022.	2.0	10
436	Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. <i>Revue Neurologique</i> , 2019, 175, 233-237.	0.6	22
437	Safety and Tolerability of Pharmacotherapies for Parkinsonâ€™s Disease in Geriatric Patients. <i>Drugs and Aging</i> , 2019, 36, 511-530.	1.3	38
438	Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 86.	1.1	41
439	Impulsivity across reactive, proactive and cognitive domains in Parkinson's disease on dopaminergic medication: Evidence for multiple domain impairment. <i>PLoS ONE</i> , 2019, 14, e0210880.	1.1	8
440	Neuropsychiatric Traits Associated with Refractory Impulse Control Disorder in Parkinsonâ€™s Disease. <i>Neurodegenerative Diseases</i> , 2019, 19, 171-177.	0.8	4
441	About the Misleading Use of Stereodescriptors in Labeling the Stereoisomers of Milnacipran and Levomilnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 673-674.	0.7	0
442	Parkinson's disease: Diagnosis and appreciation of comorbidities. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 167, 257-277.	1.0	7
443	Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 675-676.	0.7	4
444	Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 30-37.	0.9	16
445	Dopaminergic influences on risk preferences of Parkinsonâ€™s disease patients. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2019, 19, 88-97.	1.0	11
446	Pharmacological insights into impulsiveâ€“compulsive spectrum disorders associated with dopaminergic therapy. <i>European Journal of Neuroscience</i> , 2019, 50, 2492-2502.	1.2	9
447	Iowa Gambling Task Performance in Parkinson Disease Patients with Impulse Control Disorders. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 310-318.	0.3	11

#	ARTICLE	IF	CITATIONS
448	Impulse control disorders in Parkinson's disease versus in healthy controls: A different predictive model. <i>Journal of Neuropsychology</i> , 2020, 14, 318-332.	0.6	7
449	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2165-2174.	3.3	5
450	Dopaminergic signaling of uncertainty and the aetiology of gambling addiction. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109853.	2.5	22
451	Management of Urologic and Sexual Dysfunction in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 69-80.	1.0	12
452	Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. <i>Growth Hormone and IGF Research</i> , 2020, 55, 101356.	0.5	6
453	Sexual function and depressive symptoms in young women with hypoprolactinaemia. <i>Clinical Endocrinology</i> , 2020, 93, 482-488.	1.2	10
454	"Dopamine agonist Phobia" in Parkinson's disease: when does it matter? Implications for non-motor symptoms and personalized medicine. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 953-965.	1.4	7
455	Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. <i>Frontiers in Endocrinology</i> , 2020, 11, 579606.	1.5	19
456	Too much of a good thing: hedonistic homeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 566-567.	0.9	2
457	Neurobiology of cue-reactivity, craving, and inhibitory control in non-substance addictive behaviors. <i>Journal of the Neurological Sciences</i> , 2020, 415, 116952.	0.3	72
458	Management of psychiatric disorders in Parkinson's disease. <i>Neurotherapeutics</i> , 2020, 17, 1511-1524.	2.1	19
459	Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 591-598.	0.9	4
461	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. <i>Npj Parkinson's Disease</i> , 2020, 6, 6.	2.5	5
462	Behavioral and Neuroanatomical Account of Impulsivity in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1338.	1.1	20
463	The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism. <i>European Neuropsychopharmacology</i> , 2020, 32, 104-119.	0.3	4
464	The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 102, 109942.	2.5	25
465	Measuring impulsivity in Parkinson's disease: a correlational and structural neuroimaging study using different tests. <i>European Journal of Neurology</i> , 2020, 27, 1478-1486.	1.7	6
466	Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson's disease to healthy controls. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 425-435.	0.8	3

#	ARTICLE	IF	CITATIONS
467	Personality dimensions of patients can change during the course of parkinsonâ€™s disease. PLoS ONE, 2021, 16, e0245142.	1.1	5
468	Cognitive and Behavioral Inhibition Deficits in Parkinsonâ€™s Disease: The Hayling Test as a Reliable Marker. Frontiers in Aging Neuroscience, 2020, 12, 621603.	1.7	7
469	The effect of psychological and medical conditions on sexuality. , 2021, , 195-234.		0
470	Degenerative Movement Disorders of the Central Nervous System. , 2021, , 972-982.		0
471	Sexual Disorders and Quality of Life in Parkinson's Disease. Sexual Medicine, 2021, 9, 100280-100280.	0.9	16
472	Noradrenergic contributions to cue-driven risk-taking and impulsivity. Psychopharmacology, 2021, 238, 1765-1779.	1.5	10
473	Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study. Endocrinologia, Diabetes Y Nutrici3n, 2022, 69, 279-288.	0.1	3
475	Discontinuation of Dopamine Agonists in Parkinsonâ€™s Disease: A Retrospective Analysis. OsmangazÄ° Journal of Medicine, 0, , .	0.1	0
476	Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex. Journal of Parkinson's Disease, 2021, 11, 1091-1115.	1.5	10
477	The role of dopamine in action control: Insights from medication effects in Parkinsonâ€™s disease. Neuroscience and Biobehavioral Reviews, 2021, 127, 158-170.	2.9	12
478	Analysis of Impulse Control Disorders (ICDs) and Factors Associated with Their Development in a Parkinsonâ€™s Disease Population. Healthcare (Switzerland), 2021, 9, 1263.	1.0	1
479	Editorial Comment: Sexual Dysfunction in Parkinson Disease: A Multicenter Italian Cross-sectional Study on a Still Overlooked Problem. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 1057-1060.	0.7	0
480	3D fuzzy graphene microelectrode array for dopamine sensing at sub-cellular spatial resolution. Biosensors and Bioelectronics, 2021, 191, 113440.	5.3	25
481	Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7.		0
482	Impulse Control Disorders. Neuropsychiatric Symptoms of Neurological Disease, 2015, , 79-98.	0.3	2
483	DBS Innovations in the Near Future?. , 2019, , 159-172.		1
485	Neurotoxic Effects of Pharmaceutical Agents III: Neurological Agents. , 2009, , 358-371.		2
486	Depression and Psychosis in Neurological Practice. , 2012, , 92-116.		10

#	ARTICLE	IF	CITATIONS
488	Dopaminergic medication improves cognitive control under low cognitive demand in Parkinson's disease.. <i>Neuropsychology</i> , 2020, 34, 551-559.	1.0	3
491	The Emergence of Devastating Impulse Control Disorders During Dopamine Agonist Therapy of the Restless Legs Syndrome. <i>Clinical Neuropharmacology</i> , 2011, 34, 66-70.	0.2	47
492	Binge Eating in Parkinson's Disease: Prevalence, Correlates and the Contribution of Deep Brain Stimulation. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, 56-62.	0.9	62
493	Impulsive Cross-Dressing in Parkinson's Disease Treated With Ropinerole. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2011, 23, E8-E8.	0.9	1
496	Deep Brain Stimulation of Nucleus Accumbens Region in Alcoholism Affects Reward Processing. <i>PLoS ONE</i> , 2012, 7, e36572.	1.1	53
497	A Conditioned Response as a Measure of Impulsive-Compulsive Behaviours in Parkinson's Disease. <i>PLoS ONE</i> , 2014, 9, e89319.	1.1	15
498	Identifying the Basal Ganglia Network Model Markers for Medication-Induced Impulsivity in Parkinson's Disease Patients. <i>PLoS ONE</i> , 2015, 10, e0127542.	1.1	20
499	Deep-Brain Stimulation of the Subthalamic Nucleus Selectively Decreases Risky Choice in Risk-Preferring Rats. <i>ENeuro</i> , 2017, 4, ENEURO.0094-17.2017.	0.9	28
500	Subthalamic Neural Activity Patterns Anticipate Economic Risk Decisions in Gambling. <i>ENeuro</i> , 2018, 5, ENEURO.0366-17.2017.	0.9	11
502	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 509-516.	0.9	9
503	Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. <i>Current Neuropharmacology</i> , 2016, 14, 356-363.	1.4	28
504	Impulse control disorders in Parkinson's disease: crossroads between neurology, psychiatry and neuroscience. <i>Behavioural Neurology</i> , 2013, 27, 547-57.	1.1	8
505	Does the brain prefer geometrical homogeneity?. <i>Behavioural Neurology</i> , 2010, 23, 101-5.	1.1	3
507	Impulse control disorders in Parkinson's disease. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	3
508	The treatment of erectile dysfunction in patients with neurogenic disease. <i>Translational Andrology and Urology</i> , 2016, 5, 88-101.	0.6	27
509	Validation of the Korean Version of the Questionnaire for Impulsive-Compulsive Disorders in		

#	ARTICLE	IF	CITATIONS
512	ADRs in a Community Hospital â€” Do These Numbers Look like Yours?; A Gaggle of â€œDermatologicâ€• Reactions â€” TEN, Iodide Mumps, Doxycycline Phototoxicity; Pergolide-Induced Ergotism; Acute Coronary Syndrome Due to Fluorouracil Infusion; Aripiprazole-Induced Acute Dystonic Reaction; Meta-Analysis: Cardiovascular Events and NSAIDs; More on Dopamine Agonists and Impulse Control Disorders. <i>Hospital Pharmacy</i> , 2006, 41, 816-904.	0.4	2
514	Entscheiden bei Morbus Parkinson â€” eine Ãœbersicht. <i>Zeitschrift fÃ¼r Neuropsychologie = Journal of Neuropsychology</i> , 2008, 19, 235-251.	0.2	0
515	Current Concepts in the Classification, Treatment, and Modeling of Pathological Gambling and Other Impulse Control Disorders. , 2008, , 317-357.		1
516	Impulse-Control Disorders. , 2008, , 305-317.		0
517	Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease. <i>Yearbook of Neurology and Neurosurgery</i> , 2008, 2008, 75-76.	0.0	0
518	Malattia di Parkinson. , 2009, , 347-369.		1
520	Medical Management of Parkinsonâ€™s Disease. , 2009, , 1507-1527.		0
523	StratÃ©gies mÃ©dicamenteuses antiparkinsoniennes. , 2011, , 155-178.		1
525	BewegungsstÃ¶rungen. , 2011, , 955-1054.		0
529	L-DOPA-Induced Disinhibition in Parkinson Disease: More than Agonistic Behavior. <i>Biological Systems, Open Access</i> , 2012, 02, .	0.1	0
530	Update in Parkinsonâ€™s Disease. , 0, , .		2
531	fMRI in Parkinsonâ€™s Disease. , 2013, , 227-238.		0
532	Dopamine agonists. , 2013, , 414-429.		0
533	How May Neuroscience Affect the Way that the Criminal Courts Deal with Addicted Offenders?. , 2013, , 279-302.		0
534	Relationship of Behavioral Addictions to Eating Disorders and Substance Use Disorders. , 2014, , 405-428.		1
535	Personality Style in Behavioural Disturbances in Parkinson's Disease. <i>Journal of Neurology & Neurophysiology</i> , 2014, 05, .	0.1	1
536	Addictions comportementales dans la maladie de Parkinson. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2014, 198, 1297-1308.	0.0	0
537	StratÃ©gies mÃ©dicamenteuses. , 2015, , 143-161.e2.		0

#	ARTICLE	IF	CITATIONS
539	Prevalence Of Impulse Control Disorders Among Adult Filipino Patients With Idiopathic Parkinsonâ€™s Disease Seen At Jose R. Reyes Memorial Medical Center. Journal of Neurological Research and Therapy, 2015, 1, 13-19.	0.2	1
540	Psychiatric Disorders. , 2016, , 127-138.		0
541	Impulse Control Behavior in Movement Disorders: Focus on Restless Leg Syndrome. , 2017, , 229-244.		0
542	Sex and Pharmacological Sexual Enhancement. , 2017, , 387-411.		0
543	Hypersexuality in Parkinsonâ€™s disease. Aktualnosci Neurologiczne, 2017, 17, 158-161.	0.1	0
544	Macroprolactinoma: Alternatives to Dopamine Agonist Therapy for Treatment of Macroprolactinomas in Patients Who Present with Psychotic Symptoms. , 2018, , 9-20.		0
547	Psychiatric Symptoms Comorbid with Neurological Syndromes. , 2019, , 201-218.		0
548	Parkinsonism and Related Disorders. , 0, , .		0
549	Definition and Classification of Parkinsonian Drugs. , 2020, , 1-30.		0
551	Hypersexuality Due to Adverse Effects of Medicines and Surgical Interventions. Health of Man, 2020, .	0.1	0
552	Intimacy, parkinsonâ€™s disease and dementia in the time of the coronavirus. Archive of Gerontology and Geriatrics Research, 2020, , 029-030.	0.3	0
553	Impulse Control Disorders associated with Pramipexole/Ropinirole Use in Non-Parkinsonâ€™s Disease: A Scoping Review. Korean Journal of Clinical Pharmacy, 2020, 30, 250-258.	0.0	0
554	Dopamine genetic risk score predicts impulse control behaviors in Parkinsonâ€™s disease. Clinical Parkinsonism & Related Disorders, 2021, 5, 100113.	0.5	3
555	Decision-Making and Impulse-Control Disorders in Parkinson's Disease. Neurological Sciences and Neurophysiology, 2020, 37, 11-17.	0.1	0
556	123I-iodoflupane dopamine transporter imaging (DaTSCAN) appearances in relation to emotional responsiveness, impulsivity and olfaction in suspected Parkinsonian syndrome. Nuclear Medicine Communications, 2020, 41, 1117-1127.	0.5	2
558	Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep, 2010, 33, 81-7.	0.6	132
559	Pramipexole and compulsive masturbation. Psychiatry, 2007, 4, 57-9.	0.3	4
561	Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iranian Journal of Neurology, 2015, 14, 86-93.	0.5	12

#	ARTICLE	IF	CITATIONS
562	Parkinson's Disease and Behavioral Addiction: the susceptibilities and risks. <i>Asian Journal of Psychiatry</i> , 2021, 68, 102960.	0.9	0
563	Prevalence, clinical presentations and impact on relationship of sexual dysfunction in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2022, 162, 1-19.	0.9	2
564	The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting. <i>Brain Research Bulletin</i> , 2022, 181, 157-166.	1.4	2
565	Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease. <i>Progress in Brain Research</i> , 2022, 269, 309-343.	0.9	10
566	Impulse control disorders, dopamine dysregulation syndrome and sex dysfunction in Parkinson's disease. <i>International Review of Neurobiology</i> , 2022, 162, 117-134.	0.9	2
567	P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. <i>Advances in Therapy</i> , 2022, 39, 1881-1894.	1.3	5
573	Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: A pilot study. <i>Endocrinología Y Nutrición (English Ed)</i> , 2022, 69, 279-288.	0.1	4
574	Genetic prediction of impulse control disorders in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 936-949.	1.7	15
575	Neural correlates of risky decision making in Parkinson's disease patients with impulse control disorders. <i>Experimental Brain Research</i> , 2022, 240, 2241-2253.	0.7	3
577	Cognitive Behavioral Therapy Plus a Serious Game as a Complementary Tool for a Patient With Parkinson Disease and Impulse Control Disorder: Case Report. <i>JMIR Serious Games</i> , 2022, 10, e33858.	1.7	1
578	Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 2261-2275.	1.5	2
579	Drug reprofiling history and potential therapies against Parkinson's disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
581	Definition and Classification of Parkinsonian Drugs. , 2022, , 2823-2852.		1
582	Should patients with Parkinson's disease only visit a neurologist's office? - a narrative review of neuropsychiatric disorders among people with Parkinson's disease. <i>Current Problems of Psychiatry</i> , 2022, 23, 220-236.	0.1	0
583	Neural correlates of impulsive compulsive behaviors in Parkinson's disease: A Japanese retrospective study. <i>NeuroImage: Clinical</i> , 2023, 37, 103307.	1.4	1
584	Altered delay discounting in neurodegeneration: insight into the underlying mechanisms and perspectives for clinical applications. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, , 105048.	2.9	2
585	Quality of life implications for elevated trait impulsivity in people with Parkinson's disease. <i>Quality of Life Research</i> , 2023, 32, 1143-1150.	1.5	1
586	D _{2/3} Agonist during Learning Potentiates Cued Risky Choice. <i>Journal of Neuroscience</i> , 2023, 43, 979-992.	1.7	5

#	ARTICLE	IF	CITATIONS
587	Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1304-1317.	1.1	2
588	Characteristics of behavioural addiction in Parkinson's disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case-control study. <i>Journal of Neural Transmission</i> , 2023, 130, 125-133.	1.4	1
591	Performance on the balloon analogue risk task and anticipatory response inhibition task is associated with severity of impulse control behaviours in people with Parkinson's disease. <i>Experimental Brain Research</i> , 2023, 241, 1159-1172.	0.7	2
592	Course of Impulse Control Disorder Symptoms in Parkinson's Disease: Deep Brain Stimulation Versus Medications. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 903-913.	0.8	2
593	Edible Bird's Nest: Seeing the Unseen. , 2023, , 115-139.		0